| Literature DB >> 30478102 |
Corinne Chmiel1, Oliver Reich2, Andri Signorell2, Stefan Neuner-Jehle1, Thomas Rosemann1, Oliver Senn1.
Abstract
OBJECTIVE: Guidelines recommend non-invasive ischaemia testing (NIIT) for the majority of patients with suspected ischaemic heart disease in a non-emergency setting. A substantial number of these patients undergo diagnostic coronary angiography (CA) without therapeutic intervention inappropriately due to lacking preceding NIIT. The aim of this study was to evaluate the effect of voluntary healthcare models with limited access on the proportion of patients without NIIT prior to elective purely diagnostic CA.Entities:
Keywords: elective coronary angiography; inappropriate; limited access insurance models; managed care; non-invasive ischemia testing; voluntary health care plans
Year: 2018 PMID: 30478102 PMCID: PMC6254409 DOI: 10.1136/bmjopen-2017-020388
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Descriptive statistics of the study population grouped into non-limited and limited access healthcare models (GK and MC)
| Non-limited access (n=5258) | Limited access (n=3915) | ||||||||
| GK (n=1816) | MC (n=2099) | ||||||||
| No NIIT | With NIIT | No NIIT | With NIIT | No NIIT | With NIIT | ||||
| High-risk (=1) | 1006 | 1692 | 2 | 287 | 577 | 2 | 306 | 644 | 2 |
| Age (mean) | 68.1 (12.8) | 67.6 (10.9) | ** 1 | 66.4 (12.5) | 66.9 (10.6) | 1 | 66.6 (13.1) | 66.6 (11.4) | 1 |
| Sex (female) | 738 | 1351 | 2 | 213 | 483 | 2 | 254 | 547 | 2 |
| Deductible | 3 | 3 | 3 | ||||||
| 300 | 1262 | 2355 | 357 | 743 | 442 | 962 | |||
| 500 | 394 | 749 | 134 | 310 | 116 | 290 | |||
| 1000 | 45 | 71 | 26 | 65 | 28 | 48 | |||
| 1500 | 59 | 127 | 24 | 51 | 23 | 55 | |||
| 2000 | 5 | 14 | 2 | 14 | 3 | 16 | |||
| 2500 | 53 | 124 | 31 | 59 | 40 | 76 | |||
| Private | 493 | 925 | 2 | 120 | 288 | 2 | 142 | 316 | 2 |
| Latin | 541 | 1066 | 2 | 195 | 466 | 2 | 55 | 116 | 2 |
| Inpatient | 1166 | 1765 | ***2 | 357 | 584 | *** | 441 | 798 | *** |
| ATC 1 | 704 | 1738 | ***2 | 219 | 648 | ***2 | 241 | 732 | ***2 |
| 2 | 576 | 1216 | **2 | 175 | 465 | **2 | 195 | 512 | *2 |
| 3 | 1114 | 2192 | 2 | 316 | 755 | **2 | 365 | 931 | ***2 |
| 4 | 277 | 510 | 2 | 72 | 152 | 2 | 80 | 185 | 2 |
| 5 | 281 | 544 | 2 | 89 | 162 | 2 | 79 | 178 | 2 |
| 6 | 1038 | 2429 | ***2 | 319 | 840 | ***2 | 348 | 985 | ***2 |
| PCG | **3 | 3 | 3 | ||||||
| <3 | 412 | 768 | 175 | 372 | 203 | 444 | |||
| 3–4 | 624 | 1342 | 200 | 474 | 221 | 557 | |||
| 5–6 | 478 | 893 | 145 | 295 | 150 | 304 | |||
| >6 | 304 | 437 | 54 | 101 | 78 | 142 | |||
Significance no NIIT vs with NIIT within non-limited access and limited access group: ***p<0.0001, **p<0.001, *p<0.01. (1) Kruskal-Wallis test, (2) Fisher exact test, (3) χ² test, pairwise comparisons between NIIT and no NIIT for each health insurance model separately. ATC, Anatomical-Therapeutic-Chemical-Classification group 1=Aspirin, platelet aggregation inhibitors, 2=statins, lipid modifying agents, 3=antihypertensives, diuretics, beta blocking agents, calcium channel blockers, agents acting on the renin-angiotensin system, 4=antidiabetics, 5=antianginous drugs, 6=antithrombotics (Categorical variable, an individual can be positive for several ATC groups); CA: coronary angiography; GK: gate keeping; Latin, French or Italian part of Switzerland compared to German part; High-risk patients: having received therapeutic cardiac intervention within one month after or 18 months prior to diagnostic CA; MC: managed care: Deductible class in Swiss Francs; NIIT: non-invasive ischaemia testing; PCG: number of chronic conditions according to pharmaceutical cost groups; Private, supplementary private hospital insurance.
Figure 1Distribution of NIIT performed according to healthcare model. OR NIIT: OR for NIIT controlled for the confounders age, sex, language area, insurance coverage, inpatient treatment, cardiovascular medication, number of chronic comorbidities and high-risk status. *P<0.001 (OR 1.17) for managed care model compared with non-limited access model (Reference). NIIT, non-invasive ischaemia testing.
Determinants for receiving non-invasive ischaemia testing before coronary angiography
| CI | OR | Sig | |
| Age (years) | 0.998 to 1.007 | 1.003 | |
| Sex (female) | 0.967 to 1.166 | 1.062 | |
| Deductible Class (Swiss Francs, Reference 300) | |||
| 500 | 0.912 to 1.141 | 1.020 | |
| 1000 | 0.667 to 1.120 | 0.865 | |
| 1500 | 0.841 to 1.374 | 1.075 | |
| 2000 | 1.082 to 4.381 | 2.177 | * |
| 2500 | 0.809 to 1.289 | 1.022 | |
| Private | 1.025 to 1.267 | 1.140 | * |
| French or Italian part of Switzerland | 0.841 to 1.044 | 0.937 | |
| Inpatient CA | 0.540 to 0.664 | 0.599 | *** |
| ATC group 1–6 | |||
| 1 | 1.251 to 1.620 | 1.423 | *** |
| 2 | 0.922 to 1.135 | 1.023 | |
| 3 | 1.002 to 1.218 | 1.104 | * |
| 4 | 0.851 to 1.115 | 0.974 | |
| 5 | 0.874 to 1.130 | 0.994 | |
| 6 | 1.034 to 1.356 | 1.184 | * |
| PCG (reference<3) | |||
| <5 | 0.940 to 1.192 | 1.058 | |
| <7 | 0.809 to 1.064 | 0.928 | |
| >=7 | 0.624 to 0.881 | 0.742 | *** |
| Limited access models (reference non-limited access) | |||
| Managed care | 1.045 to 1.312 | 1.171 | ** |
| Gate keeping | 0.991 to 1.253 | 1.114 | |
| High-risk cardiac status | 0.046443 | 0.836 | *** |
Sig: significance: ***p<0.0001, **p<0.001, *p<0.01. ATC: Anatomical-Therapeutic-Chemical-Classification group 1=Aspirin, platelet aggregation inhibitors, 2=statins, lipid modifying agents, 3=antihypertensives, diuretics, beta blocking agents, calcium channel blockers, agents acting on the renin-angiotensin system, 4=antidiabetics, 5=antianginous drugs, 6: antithrombotics (Categorical variable, an individual can be positive for several ATC groups); CA: coronary angiography; High-risk patients: having received therapeutic cardiac intervention within one month after or 18 months prior to diagnostic CA; PCG: number of chronic conditions according to pharmaceutical cost groups; Private: supplementary private hospital insurance.